Display Settings:

Format

Send to:

Choose Destination

    Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. Epub 2007 Feb 25.

    Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.

    Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM.

    Department of Chemistry, Ithaca College, Ithaca, NY 14850, USA.

    In this report, we describe new HDAC inhibitors designed to exploit a unique sub-pocket in the HDAC8 active site. These compounds were based on inspection of the available HDAC8 crystal structures bound to various inhibitors, which collectively show that the HDAC8 active site is unusually malleable and can accommodate inhibitor structures that are distinct from the canonical 'zinc binding group-linker-cap group' structures of SAHA, TSA, and similar HDAC inhibitors. Some inhibitors based on this new scaffold are >100-fold selective for HDAC8 over other class I and class II HDACs with IC(50) values <1microM against HDAC8. Furthermore, treatment of human cells with the inhibitors described here shows a unique pattern of hyperacetylated proteins compared with the broad-spectrum HDAC inhibitor TSA.

    PMID: 17346959 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Vorinostat (Zolinza®)

      Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medi...